Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Different Anti-VEGF Drugs on Fibrovascular Membrane in Proliferative Diabetic Retinopathy
ChiCTR2300067476Phase 4Completed
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Oct 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of ranibizumab, conbercept and aflibercept in diabetic retinopathy (DR) (3 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoint: Change in fibrovascular membrane neovascularization by OCTA. Started Oct 2020; status: completed.
02
Drugs
ranibizumabconberceptaflibercept
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on ChiCTR2300067476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067476.